Enforcement Report - Week of December 13, 2023
Amici's Generic Trospium Chloride Receives Approval in the U.S.
Granules Pharm`s Generic Trospium Chloride Receives Approval In US
Boston-based Karuna Pharmaceuticals originally filed for its IPO in April and began trading today. It is trading on the Nasdaq under the ticker symbol KRTX. On June 17, it set its pricing between $15 and $17 per share to raise $74.4 million.
Boston-based Karuna Pharmaceuticals originally filed for its IPO in April and began trading today. It is trading on the Nasdaq under the ticker symbol KRTX. On June 17, it set its pricing between $15 and $17 per share to raise $74.4 million.
Less than a year after raising $42 million, banking on the potential of two older drugs as an approach to fight Alzheimer’s and schizophrenia, Boston-based Karuna Pharmaceuticals on Friday laid the groundwork for a $75 million IPO.
CMO Stephen Brannan to present Phase 1 results of a multi-dose safety study aimed at optimizing combination of Xanomeline and Trospium Chloride
‘Game changing CNS’ company Karuna raises $42m A Boston-based start-up has raised $42m from investors for its potentially ‘game changing’ approach to developing new treatments for CNS conditions.
Heritage Pharms Receive FDA Nod for Trospium Chloride
Invagen Pharms ANDA Trospium Chloride Receives FDA Nod